News
Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
Alcami, a global pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Board of Directors has appointed Patrick D. Walsh as Chairman and Chief Executive Officer, effective immediately. He succeeds Walter J. Kaczmarek III, who is stepping...
News
RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Stelis Biopharma Pvt. Ltd., the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce, and supply a minimum of 200 million doses...
News
Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders
Samsung Biologics announced a strong year in 2020 as it reported 1 trillion won in target sales within just a decade at its 10th Annual General Meeting (AGM) on March 19th.
John Rim, CEO and president of Samsung Biologics, led...
News
PCR Biosystems launches advanced Bst Polymerase reagents for accelerated DNA and RNA amplification
PCR Biosystems, the UK-based specialists in DNA and RNA analysis, have launched a range of IsoFast™ Bst Polymerase reagents for rapid, robust and sensitive DNA and RNA amplification. Through its nucleic acid strand displacement capabilities, Bst polymerase eliminates the...
Clinical Trials
Moderna starts Phase I study of new Covid-19 vaccine candidate
Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children...
News
AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
Today’s agreement with the...
Drug Research
Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy
Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.
Both partners will collaborate at BioCentriq’s state-of-the art GMP facilities to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















